Neurocrine Biosciences (NBIX) Set to Announce Quarterly Earnings on Wednesday

Neurocrine Biosciences (NASDAQ:NBIX – Get Rating) will be announcing its earnings results after the market closes on Wednesday, May 4th. Analysts expect the company to announce earnings of $0.26 per share for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

Neurocrine Biosciences (NASDAQ:NBIX – Get Rating) last posted its quarterly earnings data on Friday, February 11th. The company reported ($0.08) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.61 by ($0.69). Neurocrine Biosciences had a net margin of 7.90% and a return on equity of 6.89%. The firm had revenue of $312.00 million during the quarter, compared to analyst estimates of $317.72 million. During the same period in the prior year, the company posted $3.58 earnings per share. The firm’s revenue for the quarter was up 25.9% compared to the same quarter last year. On average, analysts expect Neurocrine Biosciences to post $2 EPS for the current fiscal year and $4 EPS for the next fiscal year.

NASDAQ NBIX opened at $91.80 on Wednesday. The business has a fifty day moving average price of $92.89 and a 200 day moving average price of $88.87. Neurocrine Biosciences has a one year low of $71.88 and a one year high of $108.01. The company has a debt-to-equity ratio of 0.24, a quick ratio of 3.83 and a current ratio of 3.96. The company has a market cap of $8.77 billion, a P/E ratio of 100.88, a P/E/G ratio of 4.48 and a beta of 0.71.

In related news, insider Darin Lippoldt sold 8,455 shares of the firm’s stock in a transaction dated Tuesday, March 22nd. The stock was sold at an average price of $95.05, for a total transaction of $803,647.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Matt Abernethy sold 3,310 shares of the stock in a transaction dated Monday, February 7th. The shares were sold at an average price of $80.79, for a total value of $267,414.90. The disclosure for this sale can be found here. Insiders have sold a total of 31,743 shares of company stock valued at $2,841,371 over the last 90 days. 4.30% of the stock is currently owned by company insiders.

A number of hedge funds have recently bought and sold shares of the business. Weiss Multi Strategy Advisers LLC raised its position in Neurocrine Biosciences by 3.5% in the 4th quarter. Weiss Multi Strategy Advisers LLC now owns 34,105 shares of the company’s stock valued at $2,905,000 after purchasing an additional 1,161 shares in the last quarter. KB Financial Partners LLC acquired a new stake in Neurocrine Biosciences in the 4th quarter valued at about $33,000. Toroso Investments LLC raised its position in Neurocrine Biosciences by 21.8% in the 4th quarter. Toroso Investments LLC now owns 2,742 shares of the company’s stock valued at $234,000 after purchasing an additional 490 shares in the last quarter. California State Teachers Retirement System raised its position in Neurocrine Biosciences by 1.0% in the 4th quarter. California State Teachers Retirement System now owns 165,688 shares of the company’s stock valued at $14,112,000 after purchasing an additional 1,674 shares in the last quarter. Finally, Thrivent Financial for Lutherans raised its position in Neurocrine Biosciences by 1.1% in the 4th quarter. Thrivent Financial for Lutherans now owns 25,014 shares of the company’s stock valued at $2,130,000 after purchasing an additional 275 shares in the last quarter. 95.93% of the stock is currently owned by institutional investors.

Several research analysts recently commented on NBIX shares. Jefferies Financial Group downgraded Neurocrine Biosciences to a “hold” rating and set a $94.00 price objective for the company. in a research note on Thursday, March 3rd. StockNews.com upgraded Neurocrine Biosciences from a “hold” rating to a “buy” rating in a report on Monday, March 28th. The Goldman Sachs Group upgraded Neurocrine Biosciences from a “neutral” rating to a “buy” rating and set a $115.00 target price for the company in a report on Thursday, February 24th. HC Wainwright restated a “buy” rating and issued a $140.00 target price on shares of Neurocrine Biosciences in a report on Monday, February 14th. Finally, Morgan Stanley upped their target price on Neurocrine Biosciences from $95.00 to $100.00 and gave the company an “equal weight” rating in a report on Monday, February 14th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, Neurocrine Biosciences currently has a consensus rating of “Hold” and an average target price of $111.17.

About Neurocrine Biosciences (Get Rating)

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas.

Further Reading